Haselmeier, a leading designer and manufacturer of pen injection systems, announced that it will establish a new manufacturing facility in Bangalore, India to produce and supply high-quality, competitively priced pen injectors for the pharmaceutical industry in India. The reusable and easy-to-use pen is based on the i-pen technology and designed to allow accurate and reliable dosing.
Haselmeier has announced that Biocon, one of Asia's premier biotechnology companies, has launched INSUPen® in India. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen, for use with Biocon's insulin and insulin analogues. The first launch of the INSUPen has taken place with Biocon's Basalog® and Insugen® insulins.
Haselmeier has announced that the first application of its Axis-D pen platform has been launched. Commissioned by its client Merck Serono, a division of Merck KGaA, Germany, the new injection device has been designed to allow self injection by patients of a ready to use biopharmaceutical solution for injection.
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides drug substance as fast as 13 months at competitive prices. The novel program is called ‘Lean-to-Clinic’ and leverages Boehringer Ingelheim’s established platforms and processes for the production of monoclonal antibodies using the proprietary BI-HEX® high expression system.
Girindus Group and Axolabs announce the launch of a strategic partnership combining their skills and capabilities in oligonucleotide lead optimisation, manufacturing and analytical expertise to offer customers complete service solutions for therapeutic oligunucleotides from early discorvery and preclinical development through clinical stages and into commercialisation.
Girindus Group and Axolabs have announced the launch of a strategic partnership combining their skills and capabilities in oligonucleotide lead optimization, manufacturing and analytical expertise to offer customers complete service solutions for therapeutic oligonucleotides from early discovery and preclinical development through clinical stages and into commercialization.
Infothena eMPDExpert™ Early Adopter Program provides intensive, preferential technical and business support as well as expertise to the limited number of customers that will participate in early adoption of solution for new EVMPD regulation.
GVK Biosciences (GVK BIO), Asia’s leading drug discovery research & development organization, announced today that AstellasPharma Inc. (Tokyo:4503, “Astellas”) extended and renewed its license to the GVK BIO SAR Databases (GOSTAR).
SHL recently had the opportunity to participate, along with various other experts in the industry, in a questionnaire held by PharmTech.com on the topic of 'Pointed Debate: Expert Views on Injectables.' The article features each participant's respective insights on the injectable industry, more specifically in the area of self-administration and related technologies.
We have received a new GMP certificate, issued by the Swedish Medial Product Agency (MPA), based on an on-site inspection performed during December, 2011.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.